Search

Your search keyword '"Huang, Li Ying"' showing total 2 results
Start Over Author "Huang, Li Ying" Topic corneal neovascularization
2 results on '"Huang, Li Ying"'

1. Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept.

Author

Liu H, Ma Y, Xu HC, Huang LY, Zhai LY, and Zhang XR

Subjects
Humans, Intravitreal Injections, Macular Degeneration drug therapy, Myopia, Degenerative drug therapy, Vascular Endothelial Growth Factor A antagonists & inhibitors, Angiogenesis Inhibitors therapeutic use, Choroidal Neovascularization drug therapy, Corneal Neovascularization drug therapy, Diabetic Retinopathy drug therapy, Glaucoma, Neovascular drug therapy, Recombinant Fusion Proteins therapeutic use, Retinal Vein Occlusion drug therapy
Abstract

Purpose : To provide a detailed review on the therapeutic efficacy of conbercept for the management of ocular vasculopathies. Methods : A comprehensive literature search of various electronic databases was performed. Results : Ocular vasculopathy is one of the major causes of visual impairment and blindness which includes a range of disorders. Vascular endothelial growth factor (VEGF) regulates angiogenesis, enhances vascular permeability, and drives the formation of neovascularization. Anti-VEGF therapy has been shown to prevent vision loss or potentially improve vision in patients with exudative or neovascular retinal disease. The most recent anti-VEGF drug in China is conbercept. In the USA and Europe, bevacizumab is the most recently approved anti-VEGF agent. Conclusions : Conbercept serves as another anti-VEGF option for patients with neovascular AMD and other retinal vascular disorders. There have not been many clinical trials that study conbercept as compared with other currently available anti-VEGF drugs. There is a need for large-scale, well-designed, randomized clinical trials to ensure its long-term safety and efficacy and to determine if it has any advantages over other anti-VEGF agents.

Published
2020
Full Text
View/download PDF

2. Effects of VEGF Inhibitor Conbercept on Corneal Neovascularization Following Penetrating Keratoplasty in Rabbit Model

Author

Liu, Huan, Zhang, Xiao-Rong, Xu, Hong-Chang, Ma, Yue, Huang, Li-Ying, Zhai, Li-Ying, and Zhao, Ying

Subjects
corneal neovascularization, vascular endothelial growth factor, genetic structures, keratocan, α-smooth muscle actin, Clinical Ophthalmology, sense organs, conbercept, penetrating keratoplasty, VEGF, eye diseases, Original Research
Abstract

Huan Liu,1,2 Xiao-Rong Zhang,1,2 Hong-Chang Xu,1 Yue Ma,1 Li-Ying Huang,1 Li-Ying Zhai,1 Ying Zhao2 1Division of Ocular Injuries, Department of Ophthalmology, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, People’s Republic of China; 2Hebei OPO Eye Bank, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, People’s Republic of ChinaCorrespondence: Xiao-Rong Zhang Email zxr1110@sina.comPurpose: To evaluate the effects of the vascular endothelial growth factor inhibitor conbercept (KH902) on corneal neovascularization and wound healing following penetrating keratoplasty in rabbits.Methods: Conbercept was administered to New Zealand white rabbits through topical and subconjunctival routes. Corneal neovascularization and wound healing were examined by slit-lamp photography and histological analyses. The expressions of vascular endothelial growth factor inhibitor, α-smooth muscle actin, and keratocan in the corneal grafts were measured by real-time quantitative polymerase chain reaction (RT-qPCR).Results: The anterior segment photographs demonstrated that corneal neovascularization started in the 2nd week. In the 4th week, histologically, the superficial corneal stroma layer showed disordered arrangement, and there were large numbers of dense inflammatory cells and blood vessels in the stroma layer. Vascular endothelial growth factor in the experimental groups was significantly decreased at all time points compared with the control group (both P = 0.001). Expression of α-smooth muscle actin in corneal grafts demonstrated an increase in time even it was lower in experimental groups, but the difference was not statistically significant (P equaled to 0.507 and 0.723, respectively). There were no significant differences with the expression of keratocan in all groups except that it significantly declined at the 4th week as to the second week in all groups and P values were 0.022, 0.020 and 0.014 in control (C), topical (E1), and subconjunctival (E2) group, respectively.Conclusion: The study found that conbercept inhibited the formation of corneal neovascularization without affecting keratocan-mediated corneal wound healing and there were no significant differences between topical administration of different doses of conbercept on the rabbit corneal neovascularization after penetrating keratoplasty in this study.Keywords: α-smooth muscle actin, conbercept, corneal neovascularization, keratocan, penetrating keratoplasty, vascular endothelial growth factor, VEGF

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results